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The 17p13.1 microdeletion syndrome is a recently described genomic disorder with a core clinical phenotype of intellectual disability,
poor to absent speech, dysmorphic features, and a constellation of more variable clinical features, most prominently microcephaly. We
identified five subjects with copy-number variants (CNVs) on 17p13.1 for whom we performed detailed clinical and molecular studies.
Breakpoint mapping and retrospective analysis of published cases refined the smallest region of overlap (SRO) for microcephaly to a
genomic interval containing nine genes. Dissection of this phenotype in zebrafish embryos revealed a complex genetic architecture:
dosage perturbation of four genes (ASGR1, ACADVL, DVL2, and GABARAP) impeded neurodevelopment and decreased dosage of the
same loci caused a reduced mitotic index in vitro. Moreover, epistatic analyses in vivo showed that dosage perturbations of discrete
gene pairings induce microcephaly. Taken together, these studies support a model in which concomitant dosage perturbation of mul-
tiple genes within the CNV drive the microcephaly and possibly other neurodevelopmental phenotypes associated with rearrangements
in the 17p13.1 SRO.Introduction
Copy-number losses and gains involving different seg-
ments of the chromosome 17 short arm lead to a number
of well-characterized genomic disorders. These include
chromosome 17p13.3 duplication syndrome (MIM
613215),1 Miller-Dieker lissencephaly syndrome (MDLS
[MIM 247200]),2 Charcot-Marie-Tooth disease type 1A
(CMT1A [MIM 118220]),3 hereditary neuropathy with
liability to pressure palsies (HNPP [MIM 162500]),4
Potocki-Lupski microduplication syndrome (PTLS [MIM
610883]),5 and Smith-Magenis microdeletion syndrome
(SMS [MIM 182290]).6
The first clinical cases with 17p13.1 microdeletion syn-
drome (MIM 613776) were reported in 2009 and
20107–11 and were delineated further by Zeesman et al.,12
who described two individuals with similar clinical pheno-
types carrying de novo deletions. This study helped narrow
the critical genomic interval to <250 kb. Duplications
have been observed rarely and are associated with moder-
ate intellectual disability and mild dysmorphic fea-
tures;13,14 clinical similarity with Silver-Russell syndrome
(SRS [MIM 180860]) was reported in one case.14 In
contrast, subjects with 17p13.1 microdeletion syndrome
present marked phenotypic variability that includes severe1Department of Molecular and Human Genetics, Baylor College of Medicine, H
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The Americanintellectual disability, poor to absent speech, dysmorphic
features, and microcephaly. The variable clinical presenta-
tion may correlate with gene content and with size of the
deleted segments, which, in the literature, reveals nonre-
current events that ranged from 245 kb to 4.4 Mb. Based
on this observation, Zeesman et al.12 suggested that two
or more separate microdeletion syndromes may exist
within that entire region and that 17p13.1 microdeletion
syndrome may constitute a ‘‘contiguous gene microdele-
tion syndrome’’ as originally proposed by Schmickel.15
This is an attractive hypothesis not easy to test due to
the uniqueness of each rearrangement size as well as the
rarity of individuals with such disorders reported to date.
We identified five subjects with 17p13.1 copy-number
variants (CNVs) and performed detailed clinical evaluation
and molecular analyses of the genomic rearrangements.
Retrospective analysis of these combined data sets nar-
rowed the smallest region of overlap (SRO) associated
with microcephaly to a genomic interval containing nine
annotated loci. Functional studies in which the dosage of
each of these genes was manipulated in zebrafish embryos
provided evidence for genetic complexities. Not only did
we observe that multiple individual genes can induce
microcephaly with concomitant cell cycling defects, but
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Table 1. Clinical Presentation of Subjects with Rearrangements Spanning 17p13.1
Subject ID BAB3045 BAB3036 BAB3277 BAB3302 DECIPHER4155
CNV triplication deletion deletion deletion deletion
Inheritance de novo unknown (adopted child) unknown de novo de novo
Size 1.25 Mb 0.157 Mb 0.241 Mb 0.94 Mb 1.15 Mb
Gender F F M F F
Age 9 months 12 years 6 months 2 years 10 months 7 years 11 months 13 years
Cognitive/psych GDD GDD, nonverbal, profound ID,
ASD, severe behavior disorder
GDD, nonverbal GDD, ID, uses a
few words
GDD, profound ID,
nonverbal
Absolute/relative
microcephaly
þ/ þ/þ þ/þ / abnormal head
shape
Dysmorphic facies þ þ þ - þ
Cardiac VSD, PDA unremarkable NA NA NA
MRI brain NA unremarkable borderline to thin
corpus callosum
delayed myelination cerebral atrophy,
reduced white matter,
small cerebellum
Other proximally flexed halluces,
hypoplastic nails, unilateral
transverse palmar crease,
sensorineural hearing loss
dysplastic toenails, ligamentous
laxity, inverted nipples,
congenital entropion, bilateral
exotropia
cafe´ au lait macule,
esotropia
thoracolumbar
scoliosis, small
syrinx
joint laxity, multiple
joint dislocation,
myopia
Abbreviations are as follows: NA, not available; GDD, global developmental delay; ID, intellectual disabilities; ASD, autism spectrum disorder; VSD, ventricular
septal defect; PDA, patent ductus arteriosus.discrete gene sets. In fact, the genetic complexities revealed
from studies of 17p13.1 microdeletion syndrome have
similarities to observations for a nonrecurrent CNV on
8q24.16
These data stand in contrast to the current models for
several CNVs, the phenotype of which is driven by dosage
perturbationof a singlemajor driver: e.g.,PMP22mutations
(MIM 601097) can lead to CMT1A,3,17 subjects with TBX1
mutations (MIM 602054) can reproduce some of the phe-
notypes observed in DiGeorge/velocardiofacial syndromes
(MIM 188400/192430),18 CREBBP mutations (MIM
600140) can reproduce Rubinstein-Taybi syndrome (MIM
180894),19 and similarly forEHMT1 (MIM607001) inKleef-
stra syndrome (MIM 610253)20 and for NSD1 (MIM
606681) in Sotos syndrome (MIM 117550).21 Here we pro-
vide evidence that dosage alteration of any one of four
genes—ASGR1(MIM 108360), ACADVL (MIM 609575),
DVL2 (MIM 602151), and GABARAP (MIM 605125)—map-
ping within the SRO in humans is sufficient to cause head
size defects in zebrafish embryos potentially due to an
increased apoptosis. Furthermore, epistatic interactions be-
tween them and nearby gene products exert a contributory
effect that is likely partially responsible for the incomplete
penetrance and variable expressivity of the phenotype.Subjects and Methods
Subjects
Subjects BAB3036, BAB3045, BAB3277, and BAB3302 carrying
genomic rearrangements in 17p13.1 were identified at the Baylor
College of Medicine Medical Genetics Laboratories as part of their
clinical diagnostic evaluation. DECIPHER4155 was identified at566 The American Journal of Human Genetics 95, 565–578, NovembtheClinical GeneticsDepartment, VejleHospital (Vejle, Denmark).
Informed consent was obtained for participation in the research
study. This research was performed with the approval of the
Baylor College of Medicine Institutional Review Board (H-27609).
Clinical phenotype for each subject is described in Table 1.
We also studied further the rearrangements involving 17p13.1
in individuals DECIPHER2009 and DECIPHER2173 who were
identified in a Brazilian survey of subjects with intellectual
disability.8 From that cohort, we excluded DECIPHER2203 due
to the presence of mosaicism in 50% of white blood cells, which
could confound statistical analysis. To enlarge our sampling, we
performed a literature search for clinical reports of individuals
carrying delineated genomic alterations spanning 17p13.1. For
instance, (1) samples that were analyzed by oligonucleotide array
and/or had breakpoint junctions sequenced so that only those
with genomic data comparable in resolution to our molecular
data were utilized and (2) subjects for whom complete growth
parameters (occipitofrontal head circumference, height, weight,
and age at the time of clinical ascertainment) were available
were included here for further analysis.Clinical Laboratory Studies
Biological samples from subjects BAB3036, BAB3045, BAB3277,
and BAB3302 were studied using chromosomal microarray anal-
ysis (CMA), GTG-banded chromosome analysis, and fluorescence
in situ hybridization (FISH) at the Baylor College ofMedicineMed-
ical Genetics Laboratories as described.22 FISH to examine for the
presence of deletion or duplication involving the 17p13.1 region
was performed using BAC probes RP11-599B13 (test) and RP11-
601N13 (control).Head Circumference Analysis
Head circumference was measured as the maximal occipitofrontal
head circumference (OFC), using standard techniques. Age- ander 6, 2014
sex-matched head circumference (OFC), weight, and height (HT)
centiles were obtained using Abase, a PalmOS based calculator,
and converted into Z scores. References for height, weight, and
OFC were based on official standards for the United States/Canada
populations.23 Absolute microcephaly was defined as OFC% 1.88
SD below the mean for age and sex.24 Relative microcephaly was
calculated by adjusting the OFC to the HT (zOFC-zHT).24,25 Anal-
ysis and graphing were implemented using GraphPad Prism 5.
Refining of CNV Size and Content
To determine size, genomic extent, and gene content for each re-
arrangement, we used a customized tiling-path oligonucleotide
microarray spanning the entire 17p chromosome that was de-
signed using the Agilent e-array website. We selected 42,000
probes covering chr17: 29,000–22,100,000 (hg18), which repre-
sents an average distribution of 1 probe per 526 bp. Probe labeling
and hybridization were performed as described.25
Breakpoint Junction Sequencing and Analysis
Sample-specific primers for PCR were designed at the apparent
boundaries of the deleted or amplified segments as inferred from
the aCGH result marked by a transition from normal copy number
to copy number loss or gain. Standard PCR reactions were per-
formed using HotStartTaq Polymerase (QIAGEN), and long-range
PCR reactions were performed using TaKaRa LA Taq (Clontech).
Sequences of the primers that successfully produced PCR
sample-specific bands are shown in Table S1. PCR products were
sequenced by Sanger sequencing methodology.
Analysis of DNA sequencing was performed using UCSC
Genome Browser; similarity analysis was performed using Needle-
man-Wunsch Global Sequence Alignment Tool.
Modeling Gene-Dosage Defects in Zebrafish Embryos
Capped human mRNA corresponding to the nine genes present
within the defined SRO (ASGR1, DLG4 [MIM 602887], ACADVL,
DVL2, GABARAP, CTDNEP1 [MIM 610684], CLDN7 [MIM
609131], SLC2A4 [MIM 138190], and EIF5A [MIM 600187]) was
generated in vitro with the mMessage mMachine SP6 kit (Life
Technologies) from linearized gateway compatible vector pCS2þ
containing the cloned cDNA of interest as described.26 Capped
mRNA (100 ng) was injected into 1- to 4-cell zebrafish embryos
and scored for microcephaly at 4 dpf. At 4 dpf, embryos were fixed
in 4% paraformaldehyde and head size was measured as the dis-
tance between eyes as described.27 Splice blocking morpholinos
(sb-MOs) were designed and obtained from Gene Tools Inc.; the
sequence of eachMO is listed in Table S2; 0.5 nl of dilutedMO cor-
responding to 3 ng was injected in zebrafish embryos at 1- to 4-cell
stage and scored for microcephaly at 4 dpf. Graphs representing
the probability distribution of head size measurements generated
with the mean and standard deviation calculated from approxi-
mately 50 embryos from each condition. The Z score was calcu-
lated for the mean value for each condition compared to the
mean and standard deviation of control embryos. To test the
knockdown of gene expression, RNA was isolated using Trizol
(Life Technologies) from zebrafish embryos injected with the mor-
pholino at 1 dpf, cDNA prepared with Superscript III (Invitrogen),
and RT-PCR carried out with primers listed in Table S3.
Immunohistochemistry of Zebrafish Embryos
Zebrafish embryos at 4 dpf were fixed in freshly prepared 4% para-
formaldehyde for 6 hr and transferred to ice-cold methanol forThe American24 hr. The embryos were rehydrated to 100% PBS by a step-wise
increasing concentration of PBS with 5 min incubations followed
by bleaching in 3% hydrogen peroxide and 0.5% potassium hy-
droxide in PBS for 30 min. Embryos were blocked in 2% BSA
and 10% FBS in PBS for 30 min and incubated with anti-phospho
Histone H3 (Santa Cruz Biotechnology) at a dilution of 1:750 over-
night at 4C and secondary anti-rabbit Alexa488 at room temper-
ature for 30 min. Both antibody incubations were followed by
three washes in PBS-Tween. Zebrafish embryos were visualized
using Nikon AZ100 microscope and representative images were
generated by capturing a z stack of each embryo and merging
them. The total numbers of phospho-Histone H3-positive cells
were counted by ImageJ software using a cell counter plugin.
The number of phospho-histone-positive cells was calculated by
subtracting the number of cells in the eye from the total number
of cells obtained by tracing the head of the embryos. TUNEL assays
were carried out in 3 dpf embryos. In brief, zebrafish embryos in-
jected with 3 ng of MO were fixed in 4% PFA, bleached, treated
with proteinase K for 5 min, and post-fixed again in 4% PFA.
The TUNEL staining kit (ApopTag, Millipore) was used as per
manufacturer’s protocol; embryos were visualized with Nikon
AZ100. Images were processed in Adobe Photoshop and analyses
were carried out using ImageJ.Cell Culture, shRNA, Transfection, and Cell Cycle
Analysis
Neuro2A cells were grown in 10% FBS, DMEMmedium. To test the
expression of the nine genes in the SRO, RT-PCR was carried out
from RNA isolated from Neuro2A cells as described above, with
primers listed in Table S4. To analyze the knockdown efficiency
of each expressed gene, four to five different shRNAs expressing
pLKO.1 vector for each gene (Table S5) were obtained from Sigma.
Neuro2A cells were transfected with either nontargeting scram-
bled siRNA (Dharmacon) or a pool consisting of four targets of
siRNA against Asgr1 (Dharmacon) at a final concentration of
20 nM with Dharmafect I (Dharmacon). The remaining seven
genes in the SRO were knocked down by transfecting a pool of
0.5 mg of each pLKO.1 vector expressing shRNA targeting the
gene of interest with Dharmafect I (Dharmacon) as per manufac-
turer’s protocol. The siRNA and the shRNA sequences used for
the knockdown experiments have been listed in Table S5. At
48 hr after transfection, RNA was isolated and real-time PCR ana-
lyses were carried out to test the knockdown efficiency with
primers listed in Table S6. Cell cycle analysis was carried out by
transfecting pLKO.1 shRNA constructs as described above; 72 hr
after transfection, cells were trypsinized, resuspended in growth
medium, washed in PBS, and fixed in 4% PFA for 10 min with
0.1% TX-100 and propidium iodide (10 mg/ml) in PBS. The stain-
ing procedure was carried out on ice. Cell cycle profile was
analyzed by flow cytometry; we calculated the percentage of
S/G2/M versus G0/G1 in a population of 10,000 cells.Results
High-Resolution aCGH and Breakpoint Junction
Sequence Analysis
We studied the 17p13.1 molecular rearrangement of
seven subjects (BAB3036, BAB3045, BAB3277, BAB3302,
DECIPHER2009, DECIPHER2173, and DECIPHER4155)
with rearrangements varying in size from ~157 kb toJournal of Human Genetics 95, 565–578, November 6, 2014 567
Figure 1. High-Resolution aCGH Plot for Individuals BAB3036, BAB3277, and BAB3045
(A) Individuals with small deletions of 17p13.1 region. Black box delimits the smallest region of overlap deleted in subjects with
microcephaly.
(B) Individual with triplication involving 17p13.1 region.
CNVs were detected by oligonucleotide probes for which the mean normalized log2 (Cy5/Cy3) ratio of the CGH signal reached mean
thresholds of 1 (indicating a heterozygous deletion [CN ¼ 1]), 0.6 (indicating a duplication [CN ¼ 3]), or 1.0 (indicating a triplication
[CN ¼ 4]).2.7 Mb; five subjects (BAB3036, BAB3045, BAB3277,
BAB3302, and DECIPHER4155) are being reported for
the first time. Individual BAB3036 carries the smallest
deletion (157 kb) reported thus far for the 17p13.1 micro-
deletion syndrome (Figures 1 and 2A). Six affected individ-
uals carry nonrecurrent copy-number losses. One subject
(BAB3045) presents with a copy-number gain encompass-
ing ~1.25 Mb; normalized log2 (Cy5/Cy3) ratio of the
CGH signal reached mean thresholds of þ1.0 indicating
copy-number state (CN) ¼ 4 consistent with a triplication
(Figure 1B). The presence of four red signals corresponding
to the tested 17p13.1 region in interphase cells supports
the presence of a triplicated segment by FISH (Figure S1
available online).
We designed a variety of primer pairs to obtain the break-
point junction for each of the nonrecurrent 17p13.1 rear-
rangements. We sequenced the junction fragment of
deletions present in four individuals (BAB3036, BAB3277,
DECIPHER2009, and DECIPHER2173; Figure S2). In two
cases, BAB3277 and DECIPHER2173, deletions were medi-
ated by repetitive elements. The deletion in BAB3277
involved a pair of directly oriented LTR13A located 250
kb apart; each of those LTRs spans ~963 nt and shares
96% of nucleotide sequence similarity. The deletion in
DECIPHER2173 was mediated by two directly oriented
Alu elements, constituents of different families (AluSg
and AluY) and located 1 Mb apart in the haploid reference
genome; they share 82% nucleotide sequence identity. The
deletion observed in DECIPHER2009 also occurred be-
tween two repetitive elements (L1PA13 and AluJb), but568 The American Journal of Human Genetics 95, 565–578, Novembthere is no significant nucleotide similarity between
them; microhomology is not apparent at the junction,
which is characterized by a CCT insertion of unknown
origin. BAB3036 presents a complex breakpoint junction
that incorporated 76 nt of an AluY element located
760 kb telomeric to the rearrangement. In addition, two
point mutations within that Alu element are present: a
G>A at the breakpoint junction and a G>C located 19 nt
away from the junction (Figure S2). Mutation G>A is
not present in dbSNP; therefore, it can be either a rare
mutation present in the ancestral chromosome from
which the 76 nt insertion originated or it can be a muta-
tion generated concomitantly with the formation of
the genomic rearrangement;28 G>C is deemed to be a
single-nucleotide polymorphism (rs9894826). There is no
apparent microhomology at the breakpoint junctions of
that Alu insertion, which may be concealing polymerase
slippages in both distal and proximal strands upon the
Alu insertion (Figure S2). Replication-based mechanisms
for formation of genomic rearrangements can be error
prone and polymerase slippage can be observed at or
near breakpoint junctions.28–30
Small Head Size Associated with Rearrangements
Involving a Specific 157 kb Region
Comparative analysis of the gene content in subjects
reported here and in the literature narrowed the dosage-
sensitive SRO associated with a reduced head size or micro-
cephaly to 157 kb, spanning chr17: 6,996,378–7,152,828
(Figure 2, Table 2); six individuals presented with absoluteer 6, 2014
Figure 2. Representative Summary of CNVs Involving 17p13.1
(A) Top: Individuals with deletions are represented by green rect-
angles and the individual with a triplication is represented by
blue rectangle. The graphical normalized data for each individual
was obtained by applying the most distal and proximal oligonu-
cleotide genomic probe coordinates to the custom track at UCSC
Genome Browser website. Positions are given relative to build
hg18. Vertical blue rectangle delimits the smallest region of over-
lap (SRO) for the microcephaly phenotype in this cohort. Plus
sign indicates presence of absolute microcephaly; minus sign indi-
cates absence of absolute microcephaly (refer to Table 2 for Z score
values). N/A indicates information not available. Bottom: Dosage-
sensitive region associated with small head size (157 kb) chr17:
6,996,378–7,152,828 (hg18).
(B) Graph of Z scores of head circumferences in subjects with
17p13.1 deletions. Black dots: individual Z score of subjects who
harbor CNVs encompassing entirely predefined SRO of 157 kb.
Black squares: individual Z scores of subjects who harbor CNVs
that do not encompass predefined SRO or encompass it partially.
All measurements are plotted as age- and sex-matched Z scores.
Bars indicate mean and 95% confidence intervals.microcephaly (see Subjects and Methods for definitions),
including BAB3045, who carries a triplication. Remarkably,
the mean Z score for the head circumference (mean zOFC)
of those individuals whose deletions include the SRO is
2.46 5 0.39 (mean 5 SEM). In contrast, in subjects
carrying CNVs that do not encompass the SRO, we
observed a greater variation in the head size with a mean
zOFC of þ0.42 5 0.57. Comparison of the two groups,
using an unpaired two-tailed t test with Welch’s correc-
tion for unequal variances, showed that they differ signif-
icantly (p ¼ 0.0018). These data strongly suggest that the
genomic SRO is significantly associated with microcephalyThe American(Figure 2B), arguing that dosage-sensitive genes inside the
genetically refined and mapped SRO contribute to head
size development.
In Vivo Testing of Potential Microcephaly Drivers
To identify dosage-sensitive genes that might contribute to
microcephaly within the predefined SRO, we used overex-
pression and suppression of the human genes in zebrafish
embryos. Recent studies have shown that the systematic
assessment of dosage-sensitive genes within a CNV using
a surrogate head size assay in zebrafish embryos can poten-
tially inform the contribution of transcripts within the
CNV to head size defects in individuals with micro-
cephaly.16,27 In contrast to prior studies on the 16p11.2
CNV, in which duplication and deletion produce mirror
microcephalic and macrocephalic phenotypes, respec-
tively,25,27 both gain and loss of genetic material within
the SRO on 17p13.1 is associated with absolute micro-
cephaly (OFC % 1.88 SD; Tables 1 and 2). As a first test,
we injected 100 pg of capped human mRNA for each of
the nine human genes in the SRO into ~100 embryos at
the 1- to 4-cell stage. We then measured the distance be-
tween the eyes as a surrogate for the human microcephaly
trait25,27 at 4 days postfertilization (4 dpf), a time assessed
to be optimal for fish head size scoring.26 We set a Z score
of %1.88 as a minimum criterion for microcephaly to
mirror the clinical criteria in humans. We found that over-
expression of 7/9 genes (except DLG4 and SLC2A4)
induced significant microcephaly (Figures 3A–3C); impor-
tantly, we did not observe any significant changes in either
body length, number of somites, or the development of
the swim bladder, supporting the contention that this
phenotype was unlikely to be the result of overall develop-
mental delay.
Next, we asked whether the seven genes that induced
microcephaly when overexpressed could also give rise to
the same phenotype when suppressed. Reciprocal BLAST
of the zebrafish genome identified a direct ortholog for
6/7 genes. ASGR1 could not be detected in the zebrafish
genome and thus could not be modeled. Two other genes,
CTDNEP1 and CLDN7, have two copies in the zebrafish
genome; we focused on the respective paralogs with the
highest identity to the human protein, namely ctdnep1b
and cldn7a. For each available zebrafish orthologous
gene, we first tested the expression during development
by analysis of our in-house RNAseq data from 3 dpf and
5 dpf wild-type embryos. We detected 5–20 copies per
million for each of the six genes, with cldn7a expressed
at the lowest level among this gene set (5 copies/million);
we therefore proceeded to design splice-blocking morpho-
linos (sbMOs), which we then titrated to establish optimal
dosage, based on monitoring efficiency (by RT-PCR) and
on scoring for toxicity and nonspecific phenotypes such
as cardiac edema and gross developmental delay (Figure S3,
Tables S2 and S3).
We then injected each sbMO and tested for micro-
cephaly using the same criteria as our overexpressionJournal of Human Genetics 95, 565–578, November 6, 2014 569
Table 2. Growth Parameters for Subjects with Rearrangements at 17p13.1
Subjects Gender Age OFC (Z) HT (Z) WT (Z) zOFC-zHT
Breakpoint Junctions
Chr17 (hg18) CNV
BAB3045 F 9 months 3.1* 4.2 5 þ1.1 6,853,665–8,107,394 TRP
BAB3036 F 12 years 6 months 3.8* 1.25 þ2.5 2.55* 6,996,378–7,152,828a DEL
BAB3277 M 2 years 10 months 2.7* 0.65 þ0.7 2.05* 6,936,148–7,177,360 a DEL
BAB3302 F 7 years 11 months 0 0.45 þ0.7 þ0.45 7,033,635–7,977,678 DEL
DECIPHER20098 M NA NA NA NA NA 5,415,715–8,132,381 a DEL
DECIPHER21738 M 8 years 8 months 1.9* 0.94 0.8 0.96 6,512,788–7,567,293 a DEL
DECIPHER23468 F 5 years 1.8 1.8 1.8 0 7,033,251–7,354,034 DEL
DECIPHER4155 F 13 years NA NA NA NA 6,838,295–7,991,364 DEL
Pt 112 M 2 years 1.9* 0.1 1 1.8 6,957,207–7,209,585 DEL
Pt 212 F 8 years 3.2* 0.5 1.5 2.7* 6,991,049–7,209,612 DEL
Schwarzbraun et al.9 F at term birth þ1.7 þ1 þ1.7 0 7,066,210–7,840,187 DEL
Schluth-Bolard et al.10 M at term birth þ2 þ0.95 þ0.95 þ1.05 7,299,400–7,694,600 DEL
302611 F 33 years 0 2 2 þ2 7,300,398–8,273,016 DEL
272311 F 7 years 7 months 0.94 0.94 þ0.90 0 7,140,464–8,061,771 DEL
314811 F 5 years 9 months þ2 1.25 þ1.25 þ3.25 7,429,371–7,972,019 DEL
335411 M 3 years 6 months 1.25 þ0.5 þ0.5 1.75 5,500,927–7,937,620 DEL
Abbreviations are as follows: OFC, occipito-frontal head circumference; HT, height; WT, weight; zOFC-zHT, Z score after adjusting the OFC to the HT;
DEL: deletion; TRP: triplication. Asterisk (*) indicates values that fit absolute microcephaly (zOFC % 1.88) and relative microcephaly (zOFC-zHT % 1.88).
aBreakpoint junction coordinates based on Sanger sequencing data.studies. Suppression of 5/6 genes (acavdl, cldn7a, ctdnep1,
dvl2, and gabarap) induced significant microcephaly
(Z < 2.0), whereas eif5a was marginal (Z 1.848; Figures
3D and 3E). Three genes in particular (acadvl, dvl2, and
gabarap) had the most striking phenotype (Z scores be-
tween3.1 and4.4). The phenotype was dose dependent
and significant pathologies were not observed in other
organs that might suggest nonspecific effects. We attemp-
ted rescue experiments for the three genes associated with
the strongest phenotypes with human mRNA. Dvl2 was
intractable due to the severe phenotype induced by the
mRNA itself. For the other two genes, head size defects
were rescued (Figure S4). As an additional measure of spec-
ificity, we suppressed two genes outside the SRO, GPS2 and
CD68, both of which are expressed during early zebrafish
development and have a single direct ortholog; we did
not observe microcephaly at three different MO injection
concentrations (Figure S5).
Previous studies have shown that head size defects
are associated with a reduced number of dividing cells in
the developing brain of zebrafish embryos.27,31 To ask
whether this was the case here, we stained embryos sup-
pressed for each of acadvl, dvl2, and gabarap (the three
genes yielding the most severe phenotypes) with anti-
phospho-histone H3, a marker of dividing cells. Counting
of pH3-positive cells in 10–20 embryosmasked to injection
cocktail showed a significant reduction for each of acadvl,
dvl2, and gabarap (Figures 4A and 4B). To test whether these
changes were a result of apoptosis, we performed TUNEL570 The American Journal of Human Genetics 95, 565–578, Novembstaining on the embryos suppressed for those same three
loci. Suppression of both acadvl and dvl2 MOs resulted in
increased apoptosis as quantified by comparing TUNEL-
positive cells between morphants and controls; likewise,
suppression of gabarap induced a comparatively more
modest but still significant increase (Figures 4C and 4D).
Intrigued by this observation, and mindful of the
caution necessary when interpreting zebrafish data in the
context of mammalian pathology, we asked whether
the changes in the phospho-Histone H3 and TUNEL stain-
ing observed in the developing brain might be reflective of
mitotic defects in mammalian neuronal cells. We therefore
tested for possible effects of RNAi-mediated silencing of
the genes in the SRO on themitotic index of Neuro2A cells,
which partially retain the characteristics of neurons.32 RT-
PCR detected message for 8/9 genes in the SRO; we could
not detect Cldn7a expression (Figure S6). The siRNA pool
targeting asgr1 and the predesigned and cloned shRNA tar-
geting the remaining seven genes in the SRO were able to
efficiently knockdown the expression of all eight genes by
real-time qPCR, 48 hr posttransfection (Figure S7). Subse-
quently, whenwe performed cell cycle analysis 3 days post-
transfection, when cells were targeted with shRNA against
Acadvl, Dvl2, and Gabarap (the three genes shown in our
in vivo studies to give rise to severe microcephaly), signif-
icant reduction in the percentage of cells at S/G2/M phases
of the cell cycle was observed; Asgr1, which was intractable
to in vivo suppression, gave a similar pattern (Figure 5),
whereas the remaining testable genes not associated wither 6, 2014
Figure 3. Delimited 17p13.1 Region Harbors Dosage-Sensitive Genes as Experimentally Assayed in Zebrafish
(A) Overexpression of capped human mRNA corresponding to nine loci in the 17p13.1 region in zebrafish embryos leads to micro-
cephaly at 4 dpf. Representative dorsal images of zebrafish embryos injected with the indicated human mRNA scored for microcephaly
at 4 dpf.
(B) Graph represents the probability distribution curve of distance between eyes in zebrafish embryos upon overexpression injection of
individual mRNAs.
(C) List of individual capped human mRNAs and corresponding Z score measured as distance between eyes in zebrafish at 4 dpf (B).
(D) Graph represents the probability distribution curve of distance between eyes in zebrafish embryos injected with splice blocker
morpholinos of the indicated genes and scored for microcephaly at 4 dpf.
(E) The corresponding Z scores of the probability distribution curves in (D).overt microcephaly did not exhibit obvious cell cycle
alterations.
Genetic Interaction between Loci within the SRO
Taken together, our overexpression and suppression data
in zebrafish embryos and the cell cycle phenotypes in
mammalian neuronal cells intimated that dosage perturba-
tion of multiple genes within the 17p13.1 predefined hu-
man SRO could induce head size defects of a magnitude
analogous to what was observed in the subjects reported
here. This raised the question whether these genes mightThe Americaneach be sufficient to induce the phenotype, or whether
there might be potential gene-gene interactions within
this CNV. We therefore performed pairwise interaction ex-
periments with the six genes that gave tractable, reproduc-
ible microcephaly phenotypes in either overexpression or
suppression assays in zebrafish embryos (acadvl, dvl2,
gabarap, cldn7a, ctdnep1b, and eif5a). Each transcript was
titrated so that subeffective injection of each single MO
did not yield microcephaly; we then added MOs together
and scored 50–100 embryos per condition, masked to in-
jection cocktail. Genetic interactions that were uniqueJournal of Human Genetics 95, 565–578, November 6, 2014 571
Figure 4. Loss of the Primary Drivers of Microcephaly Lead to
Reduced Cell Division in Zebrafish
(A) Zebrafish embryos were injected with the morpholinos as indi-
cated and stained for phospho-histone H3 at 2 dpf. Representative
images are shown for control and morpholino suppression. The
dashed lines in the controls indicate the regions used for calcu-
lating the number of histone-positive cells.
(B) Graph represents average and standard error of histone-posi-
tive cells in each sample from 20 embryos.
(C) Representative images of TUNEL staining of 3 dpf zebrafish
embryos either uninjected or injected with 3 ng of acadvl, dvl2,
or gabarap MO.
(D) Graph represents the average number of TUNEL-positive cells
and standard error for each condition.
Figure 5. Loss of the Primary Drivers Result in Decreased
S/G2/M Population Neuro2A Cells
Neuro2A cells were transfected with a pool of four different siRNAs
targeting Asgr1 and compared with cells transfected with scram-
bled siRNA (Scr si). The remaining seven genes were suppressed
with a combination of five shRNAs in pLKO.1 vector for each
gene and compared against the control cells transfected with
scrambled shRNA (pLKO.1 scr). Three days after transfection, cells
were harvested, fixed, permeabilized, and stained with propidium
iodide (PI). Cell cycle analysis was carried by flow cytometry and
the average percentage of G0/G1 and S/G2/M population of
each condition from three experiments is represented and the
error bars indicate the standard deviation. **p < 0.005.for each transcript were observed (Table 3). For example,
subeffective cosuppression of acadvl and dvl2, which by
themselves yielded Z scores > 1.0, induced Z scores of
1.91, possibly indicative of an additive effect, whereas
acadvlþgabarap gave rise to Z scores of 3.5, suggesting a
multiplicative effect. By contrast, acadvlþctdnep1b gave
no appreciable phenotype (Z 0.06), whereas ctdnep1bþ
dvl2 gave the most severe phenotype (Z 5.0).Discussion
Microcephaly can have an environmental or genetic etiol-
ogy. Impaired neurogenesis seems to be the main underly-572 The American Journal of Human Genetics 95, 565–578, Novembing cause and includes defects in the mitotic apparatus,
extended or shortened cell cycle that causes disturbance
of the delicate symmetric-asymmetric division balance, de-
fects in DNA replication or genome maintenance, and
elevated rate of cell apoptosis (reviewed in Alcantara and
O’Driscoll33). Over the last two decades several genetic dis-
orders have been reported, the majority of which include
microcephaly as one of the main clinical phenotypes.
This observation supports the contention that micro-
cephaly can be an indication of perturbed cell mainte-
nance and that important gene(s) product(s) or cell
processes are profoundly deregulated.
Here we present clinical and molecular studies of five
individuals with nonrecurrent copy-number variation
encompassing the 17p13.1 region; their core clinical
phenotype includes microcephaly, dysmorphic features,
intellectual disability, and global developmental delay.
Four out of five subjects present 17p13.1 copy-number
loss whereas one subject presents 17p13.1 copy-number
gain consistent with triplication. Breakpoint analysis and
clinical assessment of newly identified subjects, combined
with published cases, identified aminimal dosage-sensitive
region of ~157 kb that is likely themajor driver of head size
defects for CNVs involving 17p13.1. This region contains
nine annotated genes, which were further modeled
in vitro and in vivo. Those assays revealed that as many
as seven dosage-sensitive transcripts exist within the SRO
segment that likely contribute to the microcephaly pheno-
type: ASGR1, ACADVL, DVL2, GABARAP, CTDNEP1,
CLDN7, and EIF5A. Among these, our in vivo modeling
data intimate at least three major genes, ACADVL, DVL2,
and GABARAP, as the primary drivers of the microcephaly
phenotype; overexpression in zebrafish and in vitroer 6, 2014
Table 3. Analysis of Pairwise Genetic Interactions for
Microcephaly Reveal Specific Loci that Sensitize the Phenotype in
Zebrafish Embryos
Gene 1 Gene 2 Z Score
acadvl – 0.98
cldn7a – 0.75
ctdnep1b – 0.35
dvl2 – 0.41
eif5a – 0.62
gabarap – 0.61
acadvl cldn7a 0.85
acadvl ctdnep1b 0.06
acadvl dvl2 1.91*
acadvl eif5a 0.07
acadvl gabarap 3.5*
cldn7a ctdnep1b 1.6
cldn7a dvl2 2.02*
cldn7a eif5a 1.3
cldn7a gabarap 3.5*
ctdnep1b dvl2 5.0*
ctdnep1b eif5a 1.3
ctdnep1b gabarap 4.2*
dvl2 eif5a 1.1
dvl2 gabarap 1.1
eif5a gabarap 0.8
Zebrafish embryos were injected with suboptimal doses (1 ng) of morpholino
and 50–100 embryos were scored at 4 dpf for the distance between eyes. The
Z scores represent the difference in distance between eyes with respect to the
control population; asterisk (*) indicates Z scores demonstrating interaction
that lead to microcephaly.modeling indicates that ASGR1 might be a fourth one. In
fact, the silencing of all four orthologous genes in a model
of mammalian neuronal cells led to reduced mitotic index.
Further TUNEL assay of cells derived from developing em-
bryos knocked down for acadvl, dvl2, and gabarap shown
an increased number of apoptotic cells.
These findings are likely to indicate the pathomechan-
ism(s) that drive clinical pathology in subjects carrying
this CNV. ASGR1 encodes the most abundant major sub-
unit of the hetero-oligomeric asialoglycoprotein receptor
(ASGPR). The asialoglycoprotein receptor is the major
lectin of hepatocytes, an integral membrane protein that
mediates endocytosis and lysosomal degradation of glyco-
proteins with exposed terminal galactose or N-acetylgalac-
tosamine residues.34 There is no obvious link between
dosage changes in ASGR1 and brain size, but our analysis
of RNA expression data of ASGR1 from 20 neuroanatomic
human brain regions available at the Allen Human Brain
Atlas indicates that this gene is expressed in several brain
regions. Furthermore, ASGR1 shows expression in fetal
brain (Human Gene Expression Atlas 2, Genomics Insti-The Americantute of the Novartis Research Foundation). Remarkably,
mutations in STAMBP (MIM 606247) that lead to dimin-
ished expression of the encoded protein deubiquinating
(DUB) isopeptidase STAMBP cause microcephaly-capillary
malformation syndrome (MIC-CAP [MIM 614261]);35
STAMBP has a key role in the regulation of cell surface re-
ceptor-mediated endocytosis and ubiquitin-dependent
sorting of receptors to lysosomes, thereby providing a pre-
cedent for dysregulation of the endocytosis pathway in the
causation of severe microcephaly.35 ACADVL encodes very
long chain acyl CoA dehydrogenase (VLCAD), an inner
mitochondrial membrane protein involved in fatty acid
b-oxidation pathway.36 Recessive mutations in ACADVL
result in VLCAD deficiency (MIM 201475), a disease char-
acterized by cardiomyopathy due the dependence of en-
ergy of cardiomyocytes on fatty acid oxidation, and rare
cases of neonatal and early childhood pathogenesis have
resulted in death.37 Obligate carriers of ACADVL muta-
tions do not present microcephaly and although there is
a minimal dependence of neurons on fatty acid oxidation
as an energy resource, it is intriguing that 1% to 5% of in-
dividuals with autism spectrum disorders have mitochon-
drial disease, highlighting the potential significance of
mitochondrial function in brain physiology.38 DVL2 is a
component of the planar cell polarity pathway (b-cate-
nin-independent Wnt signaling). Loss of Dvl2/ in mice
leads to significant lethality with increased neural crest de-
fects.39 Of interest, the expression of DVL2 is increased
significantly in subjects with glioblastoma multiforme
(GBM), a common form of malignant glioma in adults,
suggesting a role for DVL2 in uncontrolled self-renewal
of neural progenitor cells. The depletion of DVL2 in glio-
blastoma cell lines induced mitotic arrest and differentia-
tion in vitro and inhibited the formation of tumors in
immunodeficient mice due to intracranial injection of
glioblastoma cells.40 Finally, GABARAP is a Type A g-ami-
nobutyric acid receptor (GABAAR)-associated protein that
binds the g2 subunit of the receptor.41 These receptors
belong to ligand-gated ion channel family and are acti-
vated by GABA released by inhibitory axonal terminals
(reviewed in Fritschy and Brunig42). GABARAP is involved
in GABAA receptor trafficking
43 and increases channel
conductance44 and clustering on the membrane.45 In the
context of the observed defects in cell cycle profiles and
increased apoptosis in the zebrafish developing brain, we
do not yet know the precise contribution of the three
major driver genes but the contribution of dosage imbal-
ance of each transcript/protein will likely be different.
For example, Dvl2 is involved in the mitotic spindle rota-
tion, attachment to the kinetochore, and spindle assembly
checkpoint.46 By contrast, GABARAP is an integral part of
the autophagosome compartment and recently has been
shown to interact with the antiapoptotic protein Bcl-2.47
Although further studies are required to delineate the func-
tional significance of this interaction, it is possible that our
increased TUNEL-positive cells observed in embryos tar-
geted with gabarap MO might suggest a deregulation ofJournal of Human Genetics 95, 565–578, November 6, 2014 573
Figure 6. Schematic Model for Dosage-Sensitive Region at
17p13.1 Associated with Small Head Size in Human
Top: Model representing loci that leads to severe (red), moderate
(yellow), and no scored phenotype (green).
Bottom: Summary of the binary genetic interactions tested be-
tween loci for microcephaly in zebrafish embryos.the apoptotic-autophagy pathway in the brain. Finally,
suppression of the enzyme activity of ACADVL results in
increased generation of reactive oxygen species (ROS).48
Therefore, the increased apoptosis observed due to the
loss of acadvl might be a result of ROS generation.
Komoike et al.49 analyzed an individual with intellectual
disability, intractable epilepsy, and dysmorphic features
who carried a 2.3 Mb deletion in the 17p13.2p13.1 region
that overlaps with the previously identified ~180 kb SRO.49
Based on these data, DLG4 and GABARAP were tested as
potential dosage-sensitive genes associated with micro-
cephaly by morpholino suppression of the orthologs in
zebrafish. Suppression of dlg4 did not yield any appreciable
phenotype, whereas gabarapMO resulted in microcephaly
and hypoplastic mandible in 3 dpf zebrafish embryos, a
result fully concordant with our studies. These results
increase the confidence in our data; in our unbiased
approach we eliminated DLG4 as a possible candidate for
microcephaly, whereas suppression of GABARAP resulted
in severe microcephaly and constituted one of the sensi-
tizing loci for this phenotype.
CNVs associated with abnormal head size were reported
previously in genomic disorders such as those involving
16p11.2 and 1q21.1;25,50 interestingly, deletions and
duplication involving those loci lead to mirror phenotypes
(i.e., microcephaly versus macrocephaly). Nonetheless,
triplication encompassing the 17p13.1 region did not
lead to a mirror trait (i.e., macrocephaly) in the subject re-
ported here; in fact, BAB3045 presented with absolute
microcephaly (Z score 3.1) but normocephaly when
head circumference was adjusted to the height (zOFC-
zHT þ1.1). Two subjects carrying 17p13.1 deletions,
DECIPHER2173 and one individual described by Zeesman574 The American Journal of Human Genetics 95, 565–578, Novembet al.,12 also presented with absolute microcephaly, which
was less significant when adjusted to body height, suggest-
ing that subjects with copy-number alterations involving
the 17p13.1 might present with small body size (Table 2)
in some cases. Our in vivo studies indicate that apoptosis
might play an important role as the underlying disease
mechanism for this CNV. Interestingly, the list of genes
that can cause microcephaly due to excessive apoptosis
when mutated in humans seems to be growing fast. Indi-
viduals with homozygous mutation affecting the RNA
kinase involved in tRNA splicing, CLP1 (MIM 608757),
show brainmalformation andmicrocephaly; and neuronal
progenitor cells from CLP1 kinase-defective mice showed
increased cell death despite normal cell proliferation.51
Recently, dAnkle2, the Drosophila ortholog of human
ANKLE2, was identified in an X chromosome forward
screen for fly lethal recessive mutations and further
observed in a homozygous state in a subject with very
severe microcephaly and brain dysgenesis.52
Furthermore, our data indicate that microcephaly associ-
ated with CNV spanning the 17p13.1 is subject to variable
expression (Tables 1 and 2), suggesting that genes present
in that SRO are potentially affected by epistasis, a hypoth-
esis tested directly in zebrafish embryos. Our analyses re-
vealed discrete pairing of genes that can interact to drive
microcephaly and suggest that the clinical pathology is
more likely to be driven by contributory effects of each
of seven genes (Figure 6). Therefore, for this CNV, we pro-
pose a model in which epistasis within the genomic region
modulates the clinical presentation, as opposed to a model
where each gene contributes to a discrete component of
the syndromic phenotype.
Most 17p13.1 deletions are deemed to arise by recombi-
nation between repetitive elements, especially Alu-Alu
elements, in direct orientation. A previous study reported
that 67% of deletions involving that region originated
by recombination between Alu elements sharing 81%–
84% of nucleotide similarity.11 In our cohort, rearrange-
ments generated by recombination between repetitive
elements predominate: repetitive elements were present
at both breakpoints in three out of four deletions (75%)
that had breakpoints sequenced; two out of four (50%) de-
letions were mediated by these elements (DECIPHER2173,
AluSg-AluY with 82% of nucleotide similarity and
BAB3277, LTR13A-LTR13Awith 96% of nucleotide similar-
ity). Deletions mediated by repetitive elements have been
observed for a number of genomic disorder-associated
loci, often nonrecurrent rearrangements: for example, de-
letions observed in rare pathogenic CNVs,53 deletions
involving FOXL2 (MIM 605597) causing blepharophi-
mosis-ptosis-epicanthus inversus syndrome (BPES [MIM
110100]),54 deletions leading to autosomal-dominant
spastic paraplegia-4 (SPG4 [MIM 182601]),55 although
recurrent rearrangements are also observed, as the 3.4 Mb
HERV-H-mediated 3q13.2-q13.31 deletions that lead to a
syndrome marked by motor and language delay,56 and
the HERV-I-mediated AZFa deletion that causes Y-linkeder 6, 2014
spermatogenic failure (SPGFY2 [MIM 415000]).57,58 In
addition to repetitive-element-mediated events, the com-
plex rearrangement including the segmental insertion of
76 nt from a nearby AluY element in BAB3036 suggests
that replication-based mechanisms, such as fork stalling
and template switching (FoSTeS) or microhomology-medi-
ated-break-induced replication (MMBIR),28,59,60 also un-
derlie rearrangements involving 17p13.1.
In conclusion, our data support an oligogenic model for
microcephaly driven by dosage alteration of four major
genes located in a small region of 17p13.1. This contrasts
sharply with the model originally proposed by Roy
Schmickel of ‘‘contiguous gene deletion syndrome,’’
wherein each dosage-sensitive gene contributes indepen-
dently to the development of a particular clinical pheno-
type. These new data add further complexity to the
comprehension of phenotypic effects of CNVs in humans.
We recognize that our study is limited by our inability to
perturb reliably more than two genes at a time and we
cannot exclude the possibility that more complex interac-
tions exert an effect. Likewise, we do not have the dynamic
range to determine whether these interactions are additive
or multiplicative, nor did we test for potential positional
effects of genes mapping outside the SRO. Additionally,
it is possible that other genes encompassed by larger
17p13.1 CNVs or even located elsewhere in the genome
are relevant to this phenotype; in fact, modifier genes
likely have a role in defining penetrance because our data
indicate that lack of the SRO 157 kb segment is necessary
but not enough to lead to microcephaly (Figure 2). Further,
we are also cautious in interpreting functional data from
model organisms as surrogates of clinical phenotypes in
humans, especially because, for both our in vitro and
in vivo systems, it is not possible to recapitulate accurately
the haploinsufficient genotype found in humans; indeed,
our suppression studies likely exceed haploinsufficiency
and thus exaggerate the phenotypic impact of each gene
within this CNV. Nonetheless, the zebrafish model has
been shown to be useful in recapitulating micro-
cephaly,27,31,49 an observation consistent with the analo-
gous Z scores seen in embryos and in subjects carrying
17p13.1 CNVs.Supplemental Data
Supplemental Data include seven figures and six tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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